Related Experiment Video
Updated: Jun 4, 2026
Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
Assays that measure selective killing of virus-infected cells
Abstract:
When evaluating potential antiviral compounds, determining the effect of the drug on virus replication is usually the prime concern. However, since virus replication is dependent on the host cell, in circumstances where virus infection is not rapidly lytic to cells, the effect of these compounds on cell growth and viability merits consideration. Differential host cell metabolism has been reported for cells infected with viruses, e.g., HIV, measles, and HSV, and therefore it is possible that cells infected with viruses have different susceptibilities to antiviral drugs, depending on the their mode of action. Experience with HIV and a potential anti-HIV drug, EF13, showed that HIV-chronically infected cells were markedly more susceptible to EF13 than their parent uninfected cells (1); however, acutely HIV-infected cells showed a similar susceptibility as uninfected cells to EF13 (2). In addition, cells containing actively replicating HIV-1 were more susceptible to EF13 than either uninfected cells or cells infected with but not producing HIV-1 (3).
Insights
Antiviral drug efficacy depends on host cell status. Chronically infected cells show higher susceptibility to antiviral compounds like EF13 compared to uninfected or acutely infected cells.
Area of Science:
- Virology
- Cell Biology
- Pharmacology
Background:
- Antiviral drug evaluation typically focuses on viral replication inhibition.
- Host cell metabolism can be altered by viral infections (e.g., HIV, measles, HSV).
- Altered host cell metabolism may influence susceptibility to antiviral agents based on their mechanism of action.
Purpose of the Study:
- To investigate the impact of host cell infection status on antiviral drug susceptibility.
- To determine if different stages or states of viral infection alter cellular response to antiviral compounds.
Main Methods:
- Utilized human immunodeficiency virus (HIV) and a potential anti-HIV drug, EF13.
- Compared the susceptibility of uninfected cells, chronically HIV-infected cells, acutely HIV-infected cells, and cells with actively replicating HIV-1 to EF13.
Main Results:
- HIV-chronically infected cells exhibited significantly greater susceptibility to EF13 than uninfected cells.
- Acutely HIV-infected cells displayed similar susceptibility to EF13 as uninfected cells.
- Cells with actively replicating HIV-1 were more susceptible to EF13 than uninfected cells or those infected but not producing HIV-1.
Conclusions:
- Host cell infection state critically influences antiviral drug susceptibility.
- The stage of viral infection (chronic vs. acute vs. active replication) affects cellular response to antiviral compounds.
- Antiviral drug development must consider host-pathogen interactions and cellular metabolic changes.
